Receptor Pharmacology Research Hub
Binding Profiles | Selectivity | Mechanism | Pathway Analysis
peptide receptor pharmacology binding selectivity are organized here as a research-use-only reference for comparing mechanisms, quality documentation, batch traceability, and compound selection across OligoPoly Labs research peptides.
Table of Contents
Jump to the comparison tables, compound profiles, quality documentation, FAQ answers, and related OligoPoly research resources.
Receptor Binding Profiles by Compound Class
GLP-1 Receptor Family
GH Axis Receptors
Recovery Pathway Receptors
Melanocortin Receptors
Mitochondrial/Cellular
Receptor Selectivity Matrix
| Compound | GLP-1 | GIP | Glucagon | GHRH/GHSR | Melanocortin | Repair/Cellular | Mitochondrial |
|---|---|---|---|---|---|---|---|
| Semaglutide | High | None | None | None | None | None | None |
| Tirzepatide | High | High | None | None | None | None | None |
| Retatrutide | High | High | High | None | None | None | None |
| Ipamorelin | None | None | None | High | None | None | None |
| CJC-1295 | None | None | None | High | None | None | None |
| Tesamorelin | None | None | None | High | None | None | None |
| BPC-157 | None | None | None | None | None | Moderate | None |
| TB-500 | None | None | None | None | None | Moderate | None |
| PT-141 | None | None | None | None | High | None | None |
| Melanotan II | None | None | None | None | High | None | None |
| KPV | None | None | None | None | Moderate | Moderate | None |
| NAD+ | None | None | None | None | None | None | High |
Mechanism of Action by Compound
Semaglutide mechanism overview
Semaglutide is reviewed for receptor selectivity, pathway activity, and model-specific mechanism hypotheses. Review PubMed search
Tirzepatide mechanism overview
Tirzepatide is reviewed for receptor selectivity, pathway activity, and model-specific mechanism hypotheses. Review PubMed search
Retatrutide mechanism overview
Retatrutide is reviewed for receptor selectivity, pathway activity, and model-specific mechanism hypotheses. Review PubMed search
Ipamorelin mechanism overview
Ipamorelin is reviewed for receptor selectivity, pathway activity, and model-specific mechanism hypotheses. Review PubMed search
CJC-1295 mechanism overview
CJC-1295 is reviewed for receptor selectivity, pathway activity, and model-specific mechanism hypotheses. Review PubMed search
Tesamorelin mechanism overview
Tesamorelin is reviewed for receptor selectivity, pathway activity, and model-specific mechanism hypotheses. Review PubMed search
BPC-157 mechanism overview
BPC-157 is reviewed for receptor selectivity, pathway activity, and model-specific mechanism hypotheses. Review PubMed search
TB-500 mechanism overview
TB-500 is reviewed for receptor selectivity, pathway activity, and model-specific mechanism hypotheses. Review PubMed search
PT-141 mechanism overview
PT-141 is reviewed for receptor selectivity, pathway activity, and model-specific mechanism hypotheses. Review PubMed search
Melanotan II mechanism overview
Melanotan II is reviewed for receptor selectivity, pathway activity, and model-specific mechanism hypotheses. Review PubMed search
KPV mechanism overview
KPV is reviewed for receptor selectivity, pathway activity, and model-specific mechanism hypotheses. Review PubMed search
NAD+ mechanism overview
NAD+ is reviewed for receptor selectivity, pathway activity, and model-specific mechanism hypotheses. Review PubMed search
Agonist / Antagonist Classification
| Compound | Action | Research Note |
|---|---|---|
| Semaglutide | Agonist / pathway modulator | Research-use-only mechanism classification; verify against literature and batch data. |
| Tirzepatide | Agonist / pathway modulator | Research-use-only mechanism classification; verify against literature and batch data. |
| Retatrutide | Agonist / pathway modulator | Research-use-only mechanism classification; verify against literature and batch data. |
| Ipamorelin | Agonist / pathway modulator | Research-use-only mechanism classification; verify against literature and batch data. |
| CJC-1295 | Agonist / pathway modulator | Research-use-only mechanism classification; verify against literature and batch data. |
| Tesamorelin | Agonist / pathway modulator | Research-use-only mechanism classification; verify against literature and batch data. |
| BPC-157 | Agonist / pathway modulator | Research-use-only mechanism classification; verify against literature and batch data. |
| TB-500 | Agonist / pathway modulator | Research-use-only mechanism classification; verify against literature and batch data. |
| PT-141 | Agonist / pathway modulator | Research-use-only mechanism classification; verify against literature and batch data. |
| Melanotan II | Agonist / pathway modulator | Research-use-only mechanism classification; verify against literature and batch data. |
| KPV | Agonist / pathway modulator | Research-use-only mechanism classification; verify against literature and batch data. |
| NAD+ | Cellular cofactor | Research-use-only mechanism classification; verify against literature and batch data. |
Research Citations & External Databases
NIH NLM
NIH National Library of Medicine provides biomedical literature and terminology context for research review.
ClinicalTrials.gov
ClinicalTrials.gov helps researchers review study registrations and public trial context.
Receptor Pharmacology Hub FAQs
What is receptor selectivity in peptide research?
Receptor selectivity describes how strongly a compound favors one receptor or pathway compared with others.
How is GLP-1 receptor binding measured?
Binding is commonly reviewed through in vitro assays, literature data, and functional pathway models.
What is the difference between full and partial agonists?
Full agonists can produce maximal receptor response in a system, while partial agonists produce a lower maximal response.
How do dual agonists differ from single receptor compounds?
Dual agonists such as Tirzepatide are reviewed for two receptor pathways, while single receptor compounds focus on one primary pathway.
What does Ki value mean in receptor pharmacology?
Ki is an affinity estimate used to compare binding strength in controlled assay systems.
How does receptor occupancy affect research outcomes?
Occupancy can influence signaling intensity, pathway duration, and downstream model observations.
Which peptides target the GH axis receptors?
Ipamorelin, CJC-1295, Tesamorelin, and IGF-1 LR3 are commonly reviewed in GH-axis research contexts.
Where can I find binding affinity data for research peptides?
Use PubMed, product documentation, and the research library as starting references.